Karl E. Klose to Bacterial Vaccines
This is a "connection" page, showing publications Karl E. Klose has written about Bacterial Vaccines.
Connection Strength
1.307
-
Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog. 2014 Oct; 10(10):e1004439.
Score: 0.469
-
Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
Score: 0.130
-
Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112?iglB::fljB. Vaccine. 2014 Sep 08; 32(40):5234-40.
Score: 0.115
-
Sanapala S, Yu JJ, Murthy AK, Li W, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ?fopC vaccine strain. Infect Immun. 2012 Jun; 80(6):2177-85.
Score: 0.098
-
Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
Score: 0.082
-
Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
Score: 0.079
-
Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
Score: 0.075
-
Barker JR, Klose KE. Molecular and genetic basis of pathogenesis in Francisella tularensis. Ann N Y Acad Sci. 2007 Jun; 1105:138-59.
Score: 0.069
-
Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun. 2006 Apr; 74(4):2063-71.
Score: 0.065
-
Julio SM, Heithoff DM, Provenzano D, Klose KE, Sinsheimer RL, Low DA, Mahan MJ. DNA adenine methylase is essential for viability and plays a role in the pathogenesis of Yersinia pseudotuberculosis and Vibrio cholerae. Infect Immun. 2001 Dec; 69(12):7610-5.
Score: 0.048
-
Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
Score: 0.026
-
Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010 Apr 01; 5(4):e9952.
Score: 0.021
-
Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
Score: 0.019
-
Ryan ET, Crean TI, Kochi SK, John M, Luciano AA, Killeen KP, Klose KE, Calderwood SB. Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun. 2000 Jan; 68(1):221-6.
Score: 0.011